Alpha-synuclein Skin and CSF Biomarkers in Clinical Care
Description
In this presentation, we will review the evidence and knowledge gaps regarding clinical applications of CSF alpha-synuclein seed amplification assays and skin biopsies.
Neurologic Disease Biomarkers – When Are They Ready for Routine Clinical Use?*
Date: September 15, 2025
Time: 12:00 pm to 1:00 pm
Room: Essex A - C (Fourth Floor Level)
Track: Interactive Lunch Workshop
Session Description
This session will cover recent developments in biomarkers for neurologic disease. In particular, this session will examine factors that are important for consideration for when biomarkers that are well-characterized in clinical and translational research settings are appropriate to deploy in routine clinical practice. Important areas for discussion will include sensitivity, specificity, clinical utility, value, and applicability across heterogeneous patient populations.
Learning Objectives
At the conclusion of this session, attendees should be able to:
- Understand recent progress in biomarker development for neurologic diseases.
- Recognize the limitations of existing and emerging biomarkers.
- Assess areas of unmet need for future biomarker development.
Speakers
Biomarkers in Neuro-oncology
Description
This presentation will be a review of current utility of biomarkers in neuro-oncology and hope for the future.